Our specialized biopharmaceutical facility design service delivers end-to-end, risk-based engineering solutions fully compliant with current Good Manufacturing Practice (cGMP) and international pharmaceutical engineering benchmarks including ISPE Baseline Guides, FDA regulations, EMA Annex 1 and PIC/S requirementsISPE. Focused exclusively on bioprocess manufacturing demands, our cross-functional team of process architects, cleanroom engineers, MEP specialists and compliance experts align every design element with your unique biotech production workflows, covering mAbs, viral vaccines, LNP-mRNA, cell therapy and microbial fermentation production lines.
We adopt a front-loaded compliance design methodology to mitigate contamination, mix-up and environmental control risks from the conceptual stage. Core design deliverables include rational zoning of Grade A/B/C/D clean areas, strictly segregated personnel and material one-way flow systems, optimized process equipment layout, customized HVAC, pure steam, WFI, compressed clean air and process piping distribution, as well as integrated CIP/SIP, BMS and process automation infrastructure design. Our service scope covers the entire project lifecycle: site feasibility assessment, user requirement specification (URS) development, risk assessment (FMEA), schematic layout, 3D BIM detailed engineering, construction documentation, utility system design, and commissioning & qualification (CQV) design guidance.
We cater to three core project scenarios: greenfield commercial biopharma factories, compact modular containerized cleanroom plants for clinical trial production, and GMP upgrade & retrofit of legacy manufacturing facilities. All designs prioritize operational ergonomics, energy efficiency, future production line expansion, and audit readiness. By integrating GEP and GMP principles throughout every engineering stage, we help clients build audit-proof biomanufacturing plants that pass global regulatory inspections smoothly, cut operational overhead, and shorten the timeline from facility completion to commercial batch release.
